Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Fanyang Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-1328-8192; OpenAlex author ID A5041099397. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 9

  1. Integrative analysis of lactylation patterns reveals prognostic biomarkers and therapeutic targets in pancreatic cancer. Last author DOI 10.1016/j.canlet.2026.218536↗
  2. Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players. First author DOI 10.1097/cm9.0000000000003986↗
  3. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway. Co-author DOI 10.1007/s10565-024-09863-8↗
  4. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-1143↗
  5. A novel lncRNA PTTG3P/miR-132/212-3p/FoxM1 feedback loop facilitates tumorigenesis and metastasis of pancreatic cancer. Co-author DOI 10.1038/s41420-020-00360-5↗
  6. Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics. Co-author DOI 10.1158/0008-5472.can-19-1738↗
  7. VDR signaling inhibits cancer-associated-fibroblasts' release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. Co-author DOI 10.1136/gutjnl-2018-316627↗
  8. STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α. Co-author DOI 10.1158/0008-5472.can-17-0067↗
  9. Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1159/000365306↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiangyu Kong · 6 shared papers, 2014–2024 · strength 0.73
  2. Xiangyu Kong · 2 shared papers, 2026 · strength 0.64
  3. Xiulin Hu · 1 shared paper, 2026 · strength 0.36
  4. Zhaoshen Li · 1 shared paper, 2026 · strength 0.36
  5. Keping Xie · 3 shared papers, 2017–2023 · strength 0.35
  6. Zhaoshen Li · 2 shared papers, 2019–2024 · strength 0.32
  7. Tiansuo Zhao · 2 shared papers, 2020–2023 · strength 0.28
  8. Wenbo Zhu · 1 shared paper, 2026 · strength 0.28
  9. Zhaoshen Li · 1 shared paper, 2026 · strength 0.28
  10. Jiayu Chen · 1 shared paper, 2024 · strength 0.21
  11. Dacheng Xie · 2 shared papers, 2017–2020 · strength 0.18
  12. Qihui Sun · 1 shared paper, 2023 · strength 0.17
  13. Shaofei Chang · 1 shared paper, 2023 · strength 0.17
  14. Jihui Hao · 1 shared paper, 2023 · strength 0.17
  15. Fang Wei · 1 shared paper, 2023 · strength 0.17
  16. Yiqi Du · 2 shared papers, 2014–2017 · strength 0.12
  17. Lei Li · 1 shared paper, 2019 · strength 0.11
  18. Wenyu Liu · 1 shared paper, 2020 · strength 0.11
  19. Daoyan Wei · 1 shared paper, 2020 · strength 0.11
  20. Zhaoshen Li · 1 shared paper, 2020 · strength 0.11
  21. Huiqing Zhang · 1 shared paper, 2020 · strength 0.11
  22. Huiyun Zhu · 1 shared paper, 2020 · strength 0.11
  23. Liang Wang · 1 shared paper, 2020 · strength 0.11
  24. Kaixuan Wang · 1 shared paper, 2020 · strength 0.11
  25. Zhao‐Shen Li · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.